Generic drug bill
Legislation to increase FDA enforcement authority is expected to be introduced on May 15 by Rep. Dingell (D-Mich.), whose House Oversight Subcommittee has investigated the generic drug scandal for nearly two years. The measure will be referred to the Health Subcommittee, chaired by Rep. Waxman (D-Calif.), who will not be a cosponsor. Waxman reportedly is concerned that the bill's sanctions solely target the generic and not the brandname industry and that the HHS Inspector General's enforcement authority might supersede FDA's regarding FD&C Act felony violations.
You may also be interested in...
The independent, family-controlled German group has signed a third R&D pact with Danish biotech Gubra to develop poly-agonist peptides for obesity.
Inovio Pharmaceuticals has reported promising initial data from its first Phase III study of its electrical current-driven DNA plasmid-based immunotherapy, VGX-3100, in virus-associated cervical dysplasia; it is heading a small group of companies evaluating novel therapies in the condition, which often advances to cancer.
In the month ahead, a key ANDA approval could come for Viatris, while additional competition to Gilead Sciences’ Truvada for PrEP is on the way in the US following Teva and Amneal’s launches.